Strides Pharma Secures Sandoz Brands in Sub-Saharan Africa

, via its step-down subsidiary Strides Pharma International AG, has signed agreements to acquire and in-license branded generic products from Sandoz AG in key Sub-Saharan African markets including Western Sahara, Ghana, Nigeria, and Kenya. The portfolio targets anti-infective, cardiovascular, and dermatology segments, featuring brands with annual sales over $1 million, leveraging Strides' established regional footprint. The deal requires a $12 million upfront payment at closing, plus royalties tied to net sales of distributed products. Closure is anticipated by end-Q2 FY27 (September 30, 2026), pending antitrust approvals and standard conditions; Strides Pharma Global Pte Ltd provides guarantees without material impact to the parent. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.